PM Stewart, JW Tomlinson - Diabetes, 2009 - Am Diabetes Assoc An exciting era is upon us in terms of new therapies for patients with diabetes,
obesity, and metabolic syndrome. One such advance is the ability to selectively
manipulate tissue levels of glucocorticoids through targeted inhibition of ... Cited by 1 - Related articles - All 3 versions
F Salehzadeh, L Al-Khalili, SS Kulkarni, M … - Diabetes/Metabolism Reviews - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Related articles - All 2 versions
- ►nursing2008.com M Bose, B Olivan, B Laferrere - Current Opinion in Endocrinology, Diabetes and …, 2009 - journals.lww.com Introduction and background The prevalence of obesity has increased dramatically
in the USA in the last several decades. Obesity, particularly upper body obesity
(UBO), is associated with type 2 diabetes (T2DM), dyslipidemia, and ... Related articles - All 5 versions
MS Cooper, PM Stewart - Journal of Clinical Endocrinology & Metabolism, 2009 - Endocrine Soc Context: 11ß-Hydroxysteroid dehydrogenase (11ß-HSD) enzymes are now
appreciated to be im- portant regulators of hormone action at a tissue level.
11ß-HSD1 is widely expressed and increases glucocorticoid action through ... Related articles - All 3 versions
NM Morton - Adipose Tissue and Inflammation, 2009 - books.google.com 8 Glucocorticoids Modulators of Adipose as Inflammation Nicholas M. Morton
ContEnts 8.1 Adipose Inflammation in Obesity....................................
............................. 127 8.2 Glucocorticoids and Inflammation...... ... Related articles